NCT02633059View on ClinicalTrials.gov

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 30, 2015

Primary Completion Date

January 31, 2021

Study Completion Date

November 1, 2022

Conditions
Loss of Chromosome 17pRecurrent Plasma Cell Myeloma
Interventions
DRUG

Dexamethasone

Given PO

DRUG

Idasanutlin

Given PO

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (8)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Wayne State University/Karmanos Cancer Institute, Detroit

55905

Mayo Clinic, Rochester

91010

City of Hope Comprehensive Cancer Center, Duarte

32224-9980

Mayo Clinic in Florida, Jacksonville

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER